Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
暂无分享，去创建一个
R. Redfield | C. Tacket | D. Birx | J. McNeil | N. Aronson | R. Luskin-Hawk | F. Gordin | J. Brundage | N. Ruiz | E. Tramont | S. Ratto-Kim | T. Kerkering | D. Henry | M. Thompson | L. Loomis-Price | R. Garner | K. Sitz | D. Poretz | B. Yangco | R. Yarrish | C. Davis | G. Smith | P. Renzullo | L. Deyton | W. Holloway | N. Michael | P. Foster Pierce | Bienvenido G. Yangco | D. L. Birx | Gale E. Smith | Nelson L. Michael | Charles F. Davis | John F. Brundage | Fred M. Gordin | Naomi E. Aronson | Lawrence Deyton | David H. Henry | William J. Holloway | Thomas M. Kerkering | John G. McNeil | Phillip F. Pierce | Donald M. Poretz | Phil Renzullo | Nancy Ruiz | Karl V. Sitz | Melanie A. Thompson | Edmond Tramont | Robert L Yarrish | Robert R. Redfleld